Predictive Value of The Sentinel Lymph Node Biopsy (Slnb) in Early-Stage Cervical Cancer : Is Pelvic Lymphadenectomy Replaceable?

• Main Author: Garcia, A. Tejerizo
• Format: Web Resource
• Language: English
• Published: Morressier 01.01.2017
• DOI: 10.26226/morressier.5d43ffadbaa7e4c58300a78b

Predictive value of sentinel lymph node biopsy (SLNB) in early-stage cervical cancer: is pelvic lymphadenectomy replaceable?We analysed the predictive value of the sentinel lymph node biopsy (SLNB) in order to assess its safety and reliability. Retrospective analyses of patients diagnosed with early stage cervical cancer (ESCC) between June 2010 and June 2017. All patients underwent SLNB followed by pelvic lymphadenectomy (PL). Stage was IA1 to IIA1. 61 (39.8%) met the inclusion criteria. The mean tumor size was 21.1mm preoperatively. A 70% of the patients had a tumor size u22642cm. We performed 47 (77%) SLNB followed by bilateral PL. According to the technique we obtained bilateral detection in 30/47 patients (63.8%). Unilateral detection was observed in 12/47 cases (25.5%) and bilateral failure in 5/47 cases (10.6%). The lymph node status was positive in 4/47 cases (8.5%) in which para-aortic lymphadenectomy was accomplished for staging. The overall detection rate of the technique was 76.6%. We found a sensitivity of 100%, a specificity of 75.5%, a negative predictive value of 100% and a false negative rate of 0%. We observed a lymphovascular and neurological morbidity in 6.4% (3/47) and 8.5% (4/47) respectively. The SLNB would allow a decrease in the morbidity associated with PL. It seems to be a trend towards a more conservative and less aggressive surgery. Accurate selection of patients is key point.